Mustafa Sahin, MD, PhD, Neurologist-in-Chief and Chair of the Department of Neurology at Boston Children's Hospital, and his collaborators have been awarded an NIH grant of over $8.6 million for the third five-year cycle of the Rare Disease Clinical Research Network (RDCRN) project, “Developmental Synaptopathies Associated with TSC, PTEN, SHANK3, and SynGAP1 Pathogenic Variants”. This initiative represents a significant step forward in both rare disease research and patient advocacy. 

The emergence of antibiotic-resistant bacteria poses a severe threat to treating infectious diseases. To help address this challenge, Boston Children’s Hospital along with Tulane University have received $25 million in funding from NIAID/NIH to establish a Center of Excellence for Translational Research (CETR) called IMPACT (Immunization against Multidrug-resistant Pathogens: Activating T Cell Immunity).

Historically, Americans have obtained the overdose reversal drug naloxone through prescription or free distribution programs. But in September 2023, naloxone became available over the counter with the hope it would increase access to the overdose reversal treatment. A new study finds that sales of naloxone increased after it was made available to the public without a prescription, but then dipped quickly in the period following debut of over-the-counter sales.